APM
SYRS

Avidity Partners Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Avidity Partners Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,063,000
Closed -$2.29M – 86
2024
Q3 		$2.29M Sell
1,063,000
-610,538
-36% -$2.19M 0.12% 74
2024
Q2 		$8.64M Hold
1,673,538
– – 0.37% 65
2024
Q1 		$8.95M Hold
1,673,538
– – 0.32% 73
2023
Q4 		$13M Buy
1,673,538
+92,396
+6% +$316K 0.5% 56
2023
Q3 		$6.25M Buy
1,581,142
+117,108
+8% +$438K 0.25% 72
2023
Q2 		$4.61M Buy
1,464,034
+559,404
+62% +$1.8M 0.16% 83
2023
Q1 		$2.42M Buy
904,630
+4,630
+0.5% +$17.9K 0.08% 77
2022
Q4 		$3.23M Hold
900,000
– – 0.08% 72
2022
Q3 		$5.8M Buy
+900,000
New +$7.31M 0.13% 74

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $157B AUM 32.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return